Agios Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Agios Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count).
Agios Pharmaceuticals: 44 sponsored US clinical trials, 3 recruiting.
Agios Pharmaceuticals sponsors 44 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 31 completed. 7 of these trials are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 3 trials.
Top-decile sponsor footprint
Agios Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
31 of 33 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
44 total, page 1 of 1
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
NCT07241234
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants
NCT07075640
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
NCT05144256
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
NCT05175105
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT04770779
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
NCT03692052
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants
NCT06745271
Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants
NCT06648824
Single and Multiple Ascending Dose Study and Food Effect Study for AG181
NCT06286033
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
NCT05610657
Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008
NCT04995315
Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)
NCT04964323
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
NCT04696393
A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants
NCT04565678
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease
NCT04536792
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants
NCT04472832
A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants
NCT04145128
A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881
NCT04128787
A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults
NCT04015687
Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants
NCT03991312
A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
NCT03834584
A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881
NCT03960502
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007
NCT03853798
A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
NCT03548220
A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
NCT03559699
A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348
NCT03703505
Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma
NCT03361358
Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults
NCT03397329
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
NCT03282513
Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin
NCT03250598
Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects
NCT03071770
Drug-Drug Interaction Study of AG120 in Healthy Subjects
NCT02831972
Food Effect Study of AG120 in Healthy Subjects
NCT02579707
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
NCT02492737
A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency
NCT02476916
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120
NCT02489513
Food Effect Study of AG-221 in Healthy Male Subjects
NCT02218346
A Phase I Study of AG-348 in Healthy Volunteers
NCT02149966
A Phase I Study of AG-348 in Healthy Volunteers
NCT02108106
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 5 |
| Phase 3 | 7 |
Therapeutic Areas
What is open in the Agios Pharmaceuticals pipeline
3 recruiting of 44 indexed (7% open); 31 completed (70%).
Phase mix: 7 late (III/IV) vs 33 early (I/II) (early-phase heavy).
Top condition: Healthy Volunteers (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Agios Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 44 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Agios Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 44 trials (± recruiting share)
- Beth Israel Medical Center · 44 trials · 0% recruiting
- Innovative Medical · 44 trials · 0% recruiting
- Kowa Research Institute · 44 trials · 0% recruiting
- Medtronic Cardiovascular · 44 trials · 9% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Clinical Nutrition Research Center, Illinois Institute of Technology · 7% recruiting · 59 trials
- BioCryst Pharmaceuticals · 7% recruiting · 29 trials
- Genentech · 7% recruiting · 332 trials
- H. Lundbeck A/S · 7% recruiting · 72 trials
Related
What to do with this Agios Pharmaceuticals page
44 registered trials is a research-attention snapshot, not an endorsement of Agios Pharmaceuticals or any single study.
- 3 of Agios Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Agios Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Agios Pharmaceuticals pipeline card: 44 registered trials from official public datasets.Report a data error.